Distinct Plasma Immune Profile in ALS Implicates sTNFR-II in pAMPK/Leptin Homeostasis
暂无分享,去创建一个
J. Julien | N. Dupré | J. Kriz | A. Genge | P. Cordeau | V. Picher-Martel | H. Kaneb | H. Boutej | Alexandre Vézina
[1] D. Borchelt,et al. Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis , 2022, Molecular neurodegeneration.
[2] Carmen M Fernandez-Martos,et al. The potential benefit of leptin therapy against amyotrophic lateral sclerosis (ALS) , 2021, Brain and behavior.
[3] C. Kaltschmidt,et al. Neuroprotection Mediated by Human Blood Plasma in Mouse Hippocampal Slice Cultures and in Oxidatively Stressed Human Neurons , 2021, International journal of molecular sciences.
[4] J. Chowen,et al. Alterations in Leptin Signaling in Amyotrophic Lateral Sclerosis (ALS) , 2021, bioRxiv.
[5] G. Lippi,et al. Changes in Cerebrospinal Fluid Balance of TNF and TNF Receptors in Naïve Multiple Sclerosis Patients: Early Involvement in Compartmentalised Intrathecal Inflammation , 2021, Cells.
[6] A. Casrouge,et al. Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells , 2021, Proceedings of the National Academy of Sciences.
[7] R JennyVitery,et al. [Leptin sexual dimorphism, insulin resistance, and body composition in normal weight prepubescent]. , 2020, Revista chilena de pediatria.
[8] G. Logroscino,et al. Plasma Inflammatory Cytokines Are Elevated in ALS , 2020, Frontiers in Neurology.
[9] F. De Marchi,et al. Immunity in amyotrophic lateral sclerosis: blurred lines between excessive inflammation and inefficient immune responses , 2020, Brain communications.
[10] Pierpaolo Sorrentino,et al. In Amyotrophic Lateral Sclerosis Blood Cytokines Are Altered, but Do Not Correlate with Changes in Brain Topology , 2020, Brain Connect..
[11] T. Ziemssen,et al. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis , 2020, Scientific Reports.
[12] S. Wilton,et al. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? , 2019, Front. Neurosci..
[13] T. Yamashita,et al. The Effects of Leptin on Glial Cells in Neurological Diseases , 2019, Front. Neurosci..
[14] H. Wajant,et al. Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target , 2019, Expert opinion on therapeutic targets.
[15] M. Swash,et al. Interleukin-6 and amyotrophic lateral sclerosis , 2019, Journal of the Neurological Sciences.
[16] S. Appel,et al. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies , 2019, The Lancet Neurology.
[17] J. Hodges,et al. Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia , 2019, Annals of clinical and translational neurology.
[18] G. Cho,et al. Reduced sirtuin 1/adenosine monophosphate‐activated protein kinase in amyotrophic lateral sclerosis patient‐derived mesenchymal stem cells can be restored by resveratrol , 2018, Journal of tissue engineering and regenerative medicine.
[19] J. Julien,et al. Neuronal Expression of UBQLN2P497H Exacerbates TDP-43 Pathology in TDP-43G348C Mice through Interaction with Ubiquitin , 2018, Molecular Neurobiology.
[20] L. Souza,et al. Longitudinal assessment of clinical and inflammatory markers in patients with amyotrophic lateral sclerosis , 2018, Journal of the Neurological Sciences.
[21] W. Lima,et al. Insulin as a hormone regulator of the synthesis and release of leptin by white adipose tissue , 2018, Peptides.
[22] N. Wray,et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[23] J. Murabito,et al. Epigenome-Wide Association Study of Soluble Tumor Necrosis Factor Receptor 2 Levels in the Framingham Heart Study , 2018, Front. Pharmacol..
[24] A. Chiò,et al. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications , 2018, The Lancet Neurology.
[25] I. Ferrer,et al. Inflammatory Gene Expression in Whole Peripheral Blood at Early Stages of Sporadic Amyotrophic Lateral Sclerosis , 2017, Front. Neurol..
[26] Y. Itoyama,et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial , 2017, The Lancet Neurology.
[27] G. Nagel,et al. Adipokines, C-reactive protein and Amyotrophic Lateral Sclerosis – results from a population- based ALS registry in Germany , 2017, Scientific Reports.
[28] Shanker Kalyana-Sundaram,et al. Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes , 2017, JAMA neurology.
[29] D. Zang,et al. Evaluating the levels of CSF and serum factors in ALS , 2017, Brain and behavior.
[30] J. Vickers,et al. Combination treatment with leptin and pioglitazone in a mouse model of Alzheimer's disease , 2016, Alzheimer's & dementia.
[31] P. Wang,et al. Blood Plasma of Patients with Parkinson's Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity , 2016, Parkinson's disease.
[32] Y. Oiso,et al. Insulin elevates leptin secretion and mRNA levels via cyclic AMP in 3T3-L1 adipocytes deprived of glucose , 2016, Heliyon.
[33] A. Al-Chalabi,et al. Amyotrophic lateral sclerosis: moving towards a new classification system , 2016, The Lancet Neurology.
[34] G. Logroscino. Classifying change and heterogeneity in amyotrophic lateral sclerosis , 2016, The Lancet Neurology.
[35] J. Julien,et al. From animal models to human disease: a genetic approach for personalized medicine in ALS , 2016, Acta neuropathologica communications.
[36] N. Pearce,et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis , 2016, Neurology: Neuroimmunology & Neuroinflammation.
[37] B. J. Turner,et al. AMPK Signalling and Defective Energy Metabolism in Amyotrophic Lateral Sclerosis , 2016, Neurochemical Research.
[38] T. Woodruff,et al. Altered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosis , 2015, Journal of the Neurological Sciences.
[39] D. Zang,et al. Elevated Levels of IFN-γ in CSF and Serum of Patients with Amyotrophic Lateral Sclerosis , 2015, PloS one.
[40] L. Probert. TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects , 2015, Neuroscience.
[41] Y. Chern,et al. Aberrant activation of AMP‐activated protein kinase contributes to the abnormal distribution of HuR in amyotrophic lateral sclerosis , 2015, FEBS letters.
[42] J. Glass,et al. Modeling the course of amyotrophic lateral sclerosis , 2015, Nature Biotechnology.
[43] W. Robberecht,et al. The phenotypic variability of amyotrophic lateral sclerosis , 2014, Nature Reviews Neurology.
[44] P. Bossù,et al. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis , 2014, Journal of Neuroinflammation.
[45] D. Matthews,et al. Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis. , 2014, The American journal of clinical nutrition.
[46] M. Horne,et al. Mutant TDP-43 Deregulates AMPK Activation by PP2A in ALS Models , 2014, PloS one.
[47] E. Beghi,et al. Long‐term survival in amyotrophic lateral sclerosis: A population‐based study , 2014, Annals of neurology.
[48] M. Sabatelli,et al. Clinical and genetic heterogeneity of amyotrophic lateral sclerosis , 2013, Clinical genetics.
[49] P. González,et al. Acute Leptin Treatment Enhances Functional Recovery after Spinal Cord Injury , 2012, PloS one.
[50] R. Kalb,et al. Reduced Activity of AMP-Activated Protein Kinase Protects against Genetic Models of Motor Neuron Disease , 2012, The Journal of Neuroscience.
[51] K. Inoki,et al. AMPK and mTOR in cellular energy homeostasis and drug targets. , 2012, Annual review of pharmacology and toxicology.
[52] D. Wells,et al. Metformin Treatment Has No Beneficial Effect in a Dose-Response Survival Study in the SOD1G93A Mouse Model of ALS and Is Harmful in Female Mice , 2011, PloS one.
[53] S. Bouret. Neurodevelopmental actions of leptin , 2010, Brain Research.
[54] L. Kappos,et al. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis , 2009, European journal of neurology.
[55] Steven J. Greco,et al. Leptin inhibits glycogen synthase kinase-3β to prevent tau phosphorylation in neuronal cells , 2009, Neuroscience Letters.
[56] Steven J. Greco,et al. Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. , 2009, Biochemical and biophysical research communications.
[57] W. Freeman,et al. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis , 2009, Neurology.
[58] B. Mohammadi,et al. ALSFRS-R score and its ratio: A useful predictor for ALS-progression , 2008, Journal of the Neurological Sciences.
[59] M. Cuccia,et al. TNF and sTNFR1/2 plasma levels in ALS patients , 2008, Journal of Neuroimmunology.
[60] R. Chandra,et al. Elevated Inflammatory Markers in a Group of Amyotrophic Lateral Sclerosis Patients from Northern India , 2008, Neurochemical Research.
[61] Xiao-Ming Yin,et al. Leptin Protects against 6-Hydroxydopamine-induced Dopaminergic Cell Death via Mitogen-activated Protein Kinase Signaling* , 2007, Journal of Biological Chemistry.
[62] F. Zhang,et al. Neuroprotective Effects of Leptin Against Ischemic Injury Induced by Oxygen-Glucose Deprivation and Transient Cerebral Ischemia , 2007, Stroke.
[63] E. Beghi,et al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[64] C. Russell,et al. Acute and chronic regulation of leptin synthesis, storage, and secretion by insulin and dexamethasone in human adipose tissue. , 2007, American journal of physiology. Endocrinology and metabolism.
[65] W. Banks,et al. Effects of leptin on memory processing , 2006, Peptides.
[66] J. Manson,et al. A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes. , 2005, Diabetes care.
[67] F. Pi‐Sunyer,et al. Obesity‐related leptin regulates Alzheimer's Aβ , 2004 .
[68] Lisa J. Martin,et al. Leptin's sexual dimorphism results from genotype by sex interactions mediated by testosterone. , 2002, Obesity research.
[69] C. Gabay,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Leptin Directly Induces the Secretion of Interleukin 1 Receptor Antagonist in Human Monocytes* , 2022 .
[70] V. Sánchez-Margalet,et al. Human leptin stimulates proliferation and activation of human circulating monocytes. , 1999, Cellular immunology.
[71] M. Saad,et al. Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Sexual Dimorphism in Plasma Leptin Concentration* , 2022 .
[72] M. Gurney,et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.